Oncologic nuclear medicine has come to fork in the road where a choice lies between being a peripheral diagnostic technique competing against ever-evolving anatomical imaging modalities in the detection of lesions or taking a central role in the revolution in precision medicine by characterizing tumour biology and directing treatment through use of highly specific tracers. The term theranostics encapsulates the integration of diagnostics and therapeutics in the individualized management of disease (1) . Implicit in the theranostic paradigm is the assumption that results derived from a diagnostic test can precisely determine whether an individual patient is likely to benefit from a specific treatment. This underpins recent focus on companion diagnostics as an integral part of drug development. The requirement for demonstration of the presence of human epidermal growth factor receptor 2 (HER2) on a tumor in the selection of candidates for trastuzumab therapy (Herceptin®) is an excellent example of the concept of theranostics in oncology but is limited by the potential for sampling bias intrinsic in tissue biopsy. Molecular imaging of HER2 expression using radiolabeled trastuzumab provides an alternative vision of how the selection of expensive and sometimes toxic therapies might look in the future (2) . Due to its whole body imaging capability, molecular imaging with 89 Zr-trastuzumab can be used to detect heterogeneity of HER2 expression and therefore has the potential to better select patients for Herceptin® and antibody-drug conjugate therapy using this target (3) but also opens the way for therapeutic application of radionuclide therapy (4) . Beyond the expected clinical benefits of personalized medicine, theranostics could also have a significant positive economic effect. For example, KRAS is an oncoprotein that acts downstream of the epidermal growth factor receptor, and thereby predicts a poor response to anti-EGFR (epidermal growth factor receptor) therapies.
The implementation of KRAS mutation status as a companion test to exclude patients unlikely to benefit from such therapies has been estimated save a net cost of $7,500 to $12,400 per patient in the United States and €3,900 to €9,600 per patient in Germany, with equivalent clinical outcomes (5) . This economic impact becomes particularly relevant if one were contemplating introducing relatively expensive imaging biomarker studies. Given the huge relative costs of modern cancer therapies, the costs of imaging could be more than adequately offset by preventing futile or unnecessary treatments. proliferative therapy, it is interesting to note that the majority of previously progressing patients in this arm of the trial achieved disease stabilization on this therapy, supplementing data from the PROMID (6) and CLARINET (7) studies that suggest that these agents can themselves delay disease progression. This makes the results even more impressive than those achieved using targeted agents, which have generally been tested against placebo. Although the overall survival data are not yet mature and median survival has not been reached in either arm, there was reduced mortality in the PRRT arm (13 vs 22 cases). Importantly for an essentially palliative therapy, the toxicity profile of PRRT was acceptable. We believe that these data will provide a If we are to establish the theranostic paradigm as a valid method of treating cancers we believe that it is important to learn from both the successes and failures of the past. The evolution of thyroid cancer management provides an illustrative example of the key principles that are required to advance a theranostic approach. These include: Therefore, despite being somewhat specific, the radioiodine theranostic model should serve as the template for improving the efficacy of and evidence-base for therapeutic nuclear medicine.
Although immediately applicable to PRRT, it is also relevant for a range of other radionuclide therapies. There is particular excitement, for example, for targeting prostate specific membrane antigen in prostate cancer but we need to ensure that this is developed in a rigorous, scientific environment that defines the optimal therapeutic windows, optimizes tumor targeting and radiopharmaceutical delivery, minimizes radiation exposure to at-risk organs (e.g., dosimetrybased, mathematical modelling), selects the most suitable isotopes according to the tissue compartment to be targeted (Auger electrons, alpha and beta emitters), identifies agents that can modulate target expression or increase radiation-induced cellular damages (radiosensitizing agents), and encourages the combination of cytostatic treatments between radioactive sessions while identifying reliable and accurate biomarkers of therapeutic response. In order to achieve all of this, an active collaboration between different implied disciplines is necessary.
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